» Articles » PMID: 39680885

Investigating Older Adults' Perceptions of AI Tools for Medication Decisions: Vignette-Based Experimental Survey

Overview
Publisher JMIR Publications
Date 2024 Dec 16
PMID 39680885
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Given the public release of large language models, research is needed to explore whether older adults would be receptive to personalized medication advice given by artificial intelligence (AI) tools.

Objective: This study aims to identify predictors of the likelihood of older adults stopping a medication and the influence of the source of the information.

Methods: We conducted a web-based experimental survey in which US participants aged ≥65 years were asked to report their likelihood of stopping a medication based on the source of information using a 6-point Likert scale (scale anchors: 1=not at all likely; 6=extremely likely). In total, 3 medications were presented in a randomized order: aspirin (risk of bleeding), ranitidine (cancer-causing chemical), or simvastatin (lack of benefit with age). In total, 5 sources of information were presented: primary care provider (PCP), pharmacist, AI that connects with the electronic health record (EHR) and provides advice to the PCP ("EHR-PCP"), AI with EHR access that directly provides advice ("EHR-Direct"), and AI that asks questions to provide advice ("Questions-Direct") directly. We calculated descriptive statistics to identify participants who were extremely likely (score 6) to stop the medication and used logistic regression to identify demographic predictors of being likely (scores 4-6) as opposed to unlikely (scores 1-3) to stop a medication.

Results: Older adults (n=1245) reported being extremely likely to stop a medication based on a PCP's recommendation (n=748, 60.1% [aspirin] to n=858, 68.9% [ranitidine]) compared to a pharmacist (n=227, 18.2% [simvastatin] to n=361, 29% [ranitidine]). They were infrequently extremely likely to stop a medication when recommended by AI (EHR-PCP: n=182, 14.6% [aspirin] to n=289, 23.2% [ranitidine]; EHR-Direct: n=118, 9.5% [simvastatin] to n=212, 17% [ranitidine]; Questions-Direct: n=121, 9.7% [aspirin] to n=204, 16.4% [ranitidine]). In adjusted analyses, characteristics that increased the likelihood of following an AI recommendation included being Black or African American as compared to White (Questions-Direct: odds ratio [OR] 1.28, 95% CI 1.06-1.54 to EHR-PCP: OR 1.42, 95% CI 1.17-1.73), having higher self-reported health (EHR-PCP: OR 1.09, 95% CI 1.01-1.18 to EHR-Direct: OR 1.13 95%, CI 1.05-1.23), having higher confidence in using an EHR (Questions-Direct: OR 1.36, 95% CI 1.16-1.58 to EHR-PCP: OR 1.55, 95% CI 1.33-1.80), and having higher confidence using apps (EHR-Direct: OR 1.38, 95% CI 1.18-1.62 to EHR-PCP: OR 1.49, 95% CI 1.27-1.74). Older adults with higher health literacy were less likely to stop a medication when recommended by AI (EHR-PCP: OR 0.81, 95% CI 0.75-0.88 to EHR-Direct: OR 0.85, 95% CI 0.78-0.92).

Conclusions: Older adults have reservations about following an AI recommendation to stop a medication. However, individuals who are Black or African American, have higher self-reported health, or have higher confidence in using an EHR or apps may be receptive to AI-based medication recommendations.

Citing Articles

Enhancing the Clinical Relevance of Al Research for Medication Decision-Making.

Wang Q, Chen M J Med Internet Res. 2025; 27:e70657.

PMID: 39964744 PMC: 11888004. DOI: 10.2196/70657.


Authors' Reply: Enhancing the Clinical Relevance of Al Research for Medication Decision-Making.

Vordenberg S, Nichols J, Marshall V, Weir K, Dorsch M J Med Internet Res. 2025; 27:e72007.

PMID: 39964740 PMC: 11888115. DOI: 10.2196/72007.

References
1.
Vordenberg S, Rana R, Shang J, Choi J, Scherer A, Weir K . Reasons why older adults in three countries agreed with a deprescribing recommendation in a hypothetical vignette. Basic Clin Pharmacol Toxicol. 2023; 133(6):673-682. DOI: 10.1111/bcpt.13857. View

2.
Mckee M, Wouters O . The Challenges of Regulating Artificial Intelligence in Healthcare Comment on "Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It? - A Viewpoint Paper". Int J Health Policy Manag. 2022; 12:7261. PMC: 10125205. DOI: 10.34172/ijhpm.2022.7261. View

3.
Maher R, Hanlon J, Hajjar E . Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2013; 13(1):57-65. PMC: 3864987. DOI: 10.1517/14740338.2013.827660. View

4.
Reeve E, Low L, Shakib S, Hilmer S . Development and Validation of the Revised Patients' Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for Older Adults and Caregivers. Drugs Aging. 2016; 33(12):913-928. DOI: 10.1007/s40266-016-0410-1. View

5.
Alowais S, Alghamdi S, Alsuhebany N, Alqahtani T, Alshaya A, Almohareb S . Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023; 23(1):689. PMC: 10517477. DOI: 10.1186/s12909-023-04698-z. View